MoneyWorks4Me

SMS Pharmaceuticals Ltd (SMSPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532815 NSE: SMSPHARMA Pharmaceuticals & Drugs | Small Cap | SMS Pharmaceuticals Share Price

₹474.85 0.30 (0.06%)

As on 25-Sep'26 16:59

SMS Pharmaceuticals Ltd (SMSPHARMA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532815 NSE: SMSPHARMA Pharmaceuticals & Drugs | Small Cap | SMS Pharmaceuticals Share Price

₹474.85 0.30 (0.06%)

As on 25-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹4,447 Cr.
Current Price
₹474.9
52-Week Low / High
₹240 / 494
TTM EPS
₹10.9
TTM Sales
₹898 Cr.
Book Value per Share
₹86.1
P/E Ratio
43.42
Higher than its 5-year historical median
Industry PE
54.9
Price to Book (P/B)
5.52
Higher than its 5-year historical median
Price to Sales (P/S)
4.95
Higher than its 5-year historical median
EV/EBITDA
26.13
Higher than its 5-year historical median
Dividend Yield
0.08%
Profitability Efficiency
Return on Equity (ROE)
12.49%
Outperforms industry median
Return on Capital Employed (ROCE)
13.32%
Outperforms industry median
Return on Assets (ROA)
6.87%
Operating Profit Margin
19.3%
Net Profit Margin
9.92%
Gross Profit Margin
15.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
13.3%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
23.43%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
30.56%
Asset Quality
Promoter Holding
68.07%
Pledged shares (%) of Promoter's holding (%)
17.99%
Reserves
₹797 Cr.
Equity
₹9.4 Cr.
Face Value
₹1
All Time Low / High
₹7.21 / 494.40

SMS Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Overvalued

Price Trend

Strong
Q.1 Is SMS Pharmaceuticals Ltd a good quality company?
SMS Pharmaceuticals Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does SMS Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of SMS Pharmaceuticals Ltd vs industry peers?
SMS Pharmaceuticals Ltd revenue CAGR is 9.51%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of SMS Pharmaceuticals Ltd?
Promoters hold 68.07% of the SMS Pharmaceuticals Ltd, with 17.99% of their stake pledged, indicating high pledge risk.
Q.1 Stock return of SMS Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 17% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
SMS Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ12.6%17.7%16%12.6%17.1%12.3%3.7%11.3%12.2%13%-
Value Creation
Index ⓘ
-0.10.30.1-0.10.2-0.1-0.7-0.2-0.1-0.1-

Growth Parameters ⓘ

Sales ⓘ438463465412563520522709783887898
Sales YoY Gr.-5.6%0.5%-11.4%36.7%-7.7%0.4%35.9%10.4%13.3%-
Adj EPS ⓘ4.24.74.83.77.27.80.25.67.38.99.7
YoY Gr.-13.2%2.1%-22.8%92.5%9.2%-98%3400%30.5%22.3%-
BVPS (₹) ⓘ3135.640.243.450.658.358.56474.185.988.2
Adj Net
Profit ⓘ
35.339.940.831.560.666.21.447.464.883.791
Cash Flow from Ops. ⓘ73.531.849.839.790.545.122.550.181.760.7-
Debt/CF from Ops. ⓘ24.62.93.82.85.811.35.63.86-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ8.2%9.5%19.3%13.3%
Adj EPS ⓘ8.8%4.5%282.3%22.3%
BVPSⓘ12%11.2%13.7%15.9%
Share Price 16.1% 26.2% 57.2% 88%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ
12.714.212.78.915.214.40.38.910.411.311.1
Op. Profit
Mgn % ⓘ
17.220.219.419.421.522.110.516.517.919.319.4
Net Profit
Mgn % ⓘ
8.18.68.87.610.812.70.36.78.39.410.1
Debt to
Equity ⓘ
0.60.50.40.40.60.50.50.50.50.5-
Working Cap
Days ⓘ
160128152198167215256227234220121
Cash Conv.
Cycle ⓘ
424367918212315212613713553

Valuation of SMS Pharmaceuticals - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *19.4019.4019.4019.4037.6032.4934.6517.9917.9917.99
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales438463465412563520522709783887
Operating Expenses ⓘ + 363369375332442405468593644715
Manufacturing Costs2935353440586485105111
Material Costs296290293246340275336424432493
Employee Cost 27333639415150577075
Other Costs ⓘ 12121112212018263736
Operating Profit ⓘ 7593908012111555117139172
Operating Profit Margin (%) 17.1%20.2%19.4%19.4%21.5%22.0%10.4%16.5%17.8%19.3%
Other Income ⓘ + 1235355468
Exceptional Items ⓘ 0000000000
Interest ⓘ 16151212111922241923
Depreciation ⓘ 19201922223232323440
Profit Before Tax ⓘ 42606251916856692117
Tax ⓘ 62021183011172529
Profit After Tax 3640413361684496788
PAT Margin (%) 8.1%8.7%8.9%7.9%10.8%13.1%0.7%6.9%8.6%9.9%
Adjusted EPS (₹)3.43.84.73.77.47.4-0.85.97.810.9
Dividend Payout Ratio (%)5.90%6.70%5.30%6.70%4.10%4.10%-36%6.80%5.10%3.70%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 255284322348411470461508624786
Share Capital ⓘ 8.478.478.478.478.478.478.478.478.879.37
Reserves ⓘ 246276313340402462452499615776
Debt +134130133129218217215236264323
Long Term Debt74716268147150121122139172
Short Term Debt60587161716894114125151
Minority Interest0000000000
Trade Payables673948446573107151114120
Others Liabilities ⓘ 4762709513411497154171159
Total Liabilities ⓘ 5025155726178288758801,0491,1731,388

Fixed Assets

Net Fixed Assets ⓘ +290279281280457438412437533534
Gross Block310318340361559570576631760801
Accumulated Depreciation19395880101132164193227267
CWIP ⓘ 881842711333035122
Investments ⓘ 29282726272211111226
Inventories93107136129138251223234285351
Trade Receivables2124264910649148236203216
Cash Equivalents 1213151041477364246
Others Assets ⓘ 49556881535845646493
Total Assets ⓘ 5025155726178288758801,0491,1731,388
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 73325040904522508259
PBT ⓘ 42606251916856692117
Adjustment ⓘ 32312729285053545261
Changes in Working Capital ⓘ 9-48-26-28-12-58-31-55-43-94
Tax Paid ⓘ -9-11-13-12-16-15-5-15-20-24
Cash Flow From Investing Activity ⓘ + -39-17-35-43-152-27-30-52-123-131
Capex -23-9-35-43-152-27-30-52-123-131
Net Investments -16-80-0-0-0-0-0-0-1
Others ⓘ 0000000001
Cash Flow From Financing Activity ⓘ + -33-15-13-292-12-32314776
Net Proceeds from Shares ⓘ 0000000000
Net Proceeds from Borrowing ⓘ -11-2-15188812-3472028
Interest Paid ⓘ -12-10-8-6-6-18-21-22-17-22
Dividend Paid ⓘ -2-2-3-40-3-3-3-3-4
Others ⓘ -8-112-1110-425484874
Net Cash Flow ⓘ 102-5316-392954
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)12.991513.679.7616.0715.410.8310.1611.9112.49
ROCE (%)12.7318.1716.5713.0617.6212.63.7911.7312.5513.32
Asset Turnover Ratio0.780.980.920.760.840.650.630.790.760.78
PAT to CFO Conversion(x)2.030.81.221.211.480.665.51.021.220.67
Working Capital Days
Receivable Days33.1016.7018.2030.3046.4050.806591.8094.7076.30
Inventory Days82.5073.3088.60107.5080.20128.10156.70109.10111.80115.80
Payable Days93.2066.7054.2068.305991.6098111.30112.1086.70

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

SMS Pharmaceuticals Ltd FAQs

The current trading price of SMS Pharmaceuticals on 25-Sep-2026 16:59 is ₹474.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Sep-2026 the market cap of SMS Pharmaceuticals stood at ₹4,447.1 Cr

The latest P/E ratio of SMS Pharmaceuticals as of 24-Sep-2026 is 49.12.

The latest P/B ratio of SMS Pharmaceuticals as of 24-Sep-2026 is 5.38.

The 52-week high of SMS Pharmaceuticals is ₹494.4 and the 52-week low is ₹240.4.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of SMS Pharmaceuticals is ₹898 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that SMS Pharmaceuticals Ltd is a below average quality company.

The key valuation ratios of SMS Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of SMS Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd. is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. What started off as a single facility single product manufacturing company in 1990 grew to be a multi location group having product list spreading across an array of therapeutic segments. SMS is currently a listed company having ever appreciating international and domestic customer base. Having six multi product facilities in operation, one under development, and two research centers, SMS has truly graduated in to big league with more than 600 employees working for it.

SMS Pharmaceuticals is an integrated pharma company with business presence in over 70 countries.

SMS is focused on API manufacturing and is the single largest producer of anti ulcer products and is renowned among the clientele for the excellent quality of product and customer service.

The company is diversifying into CRAMS by creating research and manufacturing facilities bettering the requirements of the regulatory markets to appeal to international clientele.

SMS is venturing into highly specialized oncology segment by building first of its kind dedicated oncology API and formulations manufacturing facility in Andhra Pradesh to target the niche market segments.

Merger of Sreenivasa Pharma Private Ltd with SMS Pharmaceuticals Ltd has given a new boost to the company, SMS Pharma has also completed the takeover of Plant Organics.

Recently SMS has established new state of art corporate research center with ultramodern facilities encompassing the whole gamut of research activity viz. from product conception to development, scaling up and DMF preparation. This is supported by well equipped analytical wing and a fully functional pilot plant. This new facility will enhance our existing offerings from a contract research and custom synthesis point of view.

R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.

SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.

Product range of the company includes:

  • API and Intermediates
  • Cytotoxic Solid Dose, Sterile Cytotoxic Liquid, and Lyophilized Products
  • Bio Products
  • Inorganic Products
  • Nutraceuticals

Different divisions of the company:

  • Manufacturing :SMS Pharmaceuticals Ltd. is one of the leading pharmaceutical manufacturing companies in India with world-class facilities with a wide range of process equipment fully compliant with WHO GMP standards.SMS has over the years developed tremendous manufacturing facilities to suit its style of operations and to meet the requirements of USFDA and other regulatory markets. A total of 6 facilities are being presently operated and one is under construction.
  • Research and development :R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.SMS research team now comprises of about 100 scientists with expertise in process research, analytical research and scale up. A dedicated project management team handles costing, administration, purchase, and project monitoring. R&D capabilities of the company span across reaction technologies, organic compound categories, and novel catalytic systems. This center is capable of delivering top notch contract research modules to international clientele.

Achievements/ recognition :

  • SMS was given the export house status in the year 1997-98.
  • Awarded the Prestigious ' Pandit Jawaharlal Nehru Silver Rolling Trophy' for the best productivity effort in the state.
  • Became the single largest producer of Ranitidine Hydrochloride in the World.
  • One of the leading export houses exporting to more than 70 countries worldwide.
  • WHO-GMP approved API manufacturing facilities in India (2 more to be operational soon).
  • Achieved ISO 9001 certification for Units at Khazipally and Bollaram.
  • Awarded the prestigious US GCNC Green chemistry award.
  • Successfull FDA audits in 2004 and 2008 at our Bachupally unit.
  • Proven expertise in low cost process routes, commercialization & manufacturing.
  • Over 21 process patents and 72 regulatory filings.
  • Successful execution of contract research and manufacturing assignments.
  • CRISIL renews SMS Pharma's SME 1 rating for FY 09-10.
  • Recieved 'Best Industrial Productivity Effort in the State' silver rolling trophy.

Future plan:

SMS is building an ultra modern API manufacturing facility near Vizag on the eastern coast of India to cater to in house production needs and also for the emerging contract manufacturing business.

You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now